Experiment 520927
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | KELSEN,D: AJANI,J: ILSON,D: DAUGHERTY,K: PAZDUR,R:. (1994). A PHASE II TRIAL OF PACLITAXEL (TAXOL) IN ADVANCE ESOPHAGEAL CANCER: PRELIMINARY REPORT.. 21(5) |
| Amount utilized | |
| Compound isolated | |
| Disease | PHASE II STUDY OF CMPD USED TO TREAT ADVANCED ESOPHAGEAL CANCER IN 42 PATIENTS. THIRTY % OF THOSE WITH ADENOCARCINOMA AND 25% OF THOSE WITH EPIDERMOID CARCINOMA SHOWED PARTIAL RESPONSES. NEUTROPENIA WAS COMMONEST SIDE-EFFECT DESPITE DOSING WITH G-CSF. |
| Dose amount | 250.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |